| Literature DB >> 31208114 |
Yin-Hwa Shih1, Tong-Hong Wang2,3,4,5, Tzong-Ming Shieh6, Yu-Hsin Tseng7.
Abstract
Oral submucous fibrosis (OSF) is characterized by abnormal collagen deposition. It is a precancerous disorder and transforms into a malignant tumor in 1.5-15% of all cases. Symptoms include submucous fibrosis, ulceration, xerostomia, a burning sensation, and restricted mouth opening. All of these greatly interfere with patient quality of life. The present review introduces OSF from a molecular perspective and summarizes what is known about its underlying mechanisms, diagnostic biomarkers, and therapeutic interventions. In addition to the aggressive treatment of OSF, its prevention is also important. Future research should, therefore, focus on improving the oral health literacy of the patients susceptible to OSF.Entities:
Keywords: collagen deposition; diagnostic biomarkers; oral submucous fibrosis (OSF); precancerous disorder; therapeutic interventions; underlying mechanisms
Mesh:
Substances:
Year: 2019 PMID: 31208114 PMCID: PMC6627879 DOI: 10.3390/ijms20122940
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1The molecular pathologic mechanism of oral submucous fibrosis (OSF).
Biomarkers in solid biopsy and liquid biopsy.
|
|
|
|
| Up: PCNA | Cell proliferation | 30 OSF, 10 OSCC [ |
| Up: cyclophilin A | Cell proliferation | 25 normal, 25 OSF [ |
| Up: NCOA7 | Cell proliferation, early diagnosis of OSF malignant transformation | 24 OSF tissues without malignant transformation, 34 OSCC tissues arising from OSF [ |
| Up: HIF-1α, PAI-1 | Angiogenesis | 6 normal, 25 OSF [ |
| Up: CD105 | Angiogenesis | 15 normal, 30 OSF [ |
| Up: α-enolase | Cell proliferation, tumorigenesis (increased Warburg effect) | 13 normal, 19 OSF without dysplasia (OSFWT), 23 OSF with dysplasia (OSFWD), 28 OSCC [ |
| Up: Ki67, cyclin D1, c-Met, IMP3Down: β-catenin | Cell proliferation (Ki67, cyclin D1), invasion (c-Met, IMP3), the combined biomarkers of Ki67 and p16 (tumor suppressor) showed significantly different expression between the transformation and non-transformation groups | 6 normal, 36 OSF [ |
| Down: WIF1 | Wnt antagonist, inhibits Wnt/β-catenin signaling by directly binding to Wnt proteins. | 15 normal tissue, 45 OSF, 55 OSCC [ |
| Up: β-catenin | Wnt/β-catenin signaling | 15 normal, 45 OSF, 55 OSCC [ |
| Down: miR-200b, miR-200c | miR-200b targeting ZEB2, miR-200c targeting ZEB1 | 25 control, 25 OSF [ |
| Down: LncRNA GAS5-AS1 | LncRNA GAS5-AS1 bind to Smads and prevents them binding to SBE on TGF-β target gene promoter, thereby negatively regulates TGF-β/Smad signaling pathway | 25 control, 25 OSF [ |
| Up: LncRNA LINC00974 | LncRNA LINC00974 activates TGF-β/Smad signaling | 20 OSF tissues [ |
|
|
|
|
| Down: Serum protein, globulin | - | 50 control, 50 nicotina stomatitis, 50 OSF, 50 leukoplakia, 50 malignancy [ |
| Up: Copper | Serum copper levels increased gradually from precancer to cancer, as the duration of betel quid chewing habit increased. | 30 control, 30 OSF, 30 OSCC [ |
| Up: Sister chromatid exchange in lymphocytes | Genotoxic, genome instability, | 10 male patients who had the habit of chewing pan for 5 or more years, 10 male patients with OSF who had panparag chewing habit and 10 age- and sex-matched controls without any chewing habit [ |
| Down: β-carotene | β-carotene as the best-known provitamin A carotenoid | 40 control, 40 OSF [ |
| Down: E-SOD, GPx | Anti-ROS stress | 25 control, 25 OSF, 25 leucoplakia, 25 OSCC [ |
| Up: LDH | Cell metabolism | 30 control, 30 OSF [ |
| Up: MDA, comet assay | ROS product (MDA), DNA damage phenotype (comet assay) | 30 control, 30 OSF [ |
|
|
|
|
| Up: 8-OHdG, MDADown: Vitamin C, vitamin E | ROS product (8-OHdG, MDA), anti-ROS stress (vitamin C, vitamin E) | 40 OSCC, 40 oral lichen planus lesions, 40 leukoplakia, 40 OSF, 40 control [ |
| Down: GPx, SOD | Anti-ROS stress | 63 control, 63 OSF [ |
| Up: LDH | LDH main function is to catalyze the oxidation of lactate to pyruvate. | 30 control, 30 OSF [ |
| Up: S100A7 | A small calcium-binding protein, has been associated with the development of psoriasis and carcinomas in different types of epithelia. | 30 control, 30 OSF [ |
|
|
|
|
| Auto-fluorescence spectroscopy, (320–330 nm excitation, collagen at 380–400 nm emission and NADH at 440–460 nm emission) | Up: Collagen | 15 normal oral mucosa, 59 OSF mucosal [ |
| OCT detect the epithelium thickness and the standard deviation of A-mode scan intensity in the laminar propria layer | Up: Epithelium thickness, laminar propria layer | 44 OSF samples were obtained |
| FTIR spectrometry | Protein contents in serum were different | 30 control, 30 OSF [ |
Summary of the conservative therapy of OSF and the molecular targets of each therapy.
|
|
|
|
| Hyperbaric oxygen treatment (HBO) | Promote the apoptosis of fibroblast, and inhibit TNF-α, TGF-β, and the activation of collagen synthesis. | [ |
|
|
|
|
| Dexamethasone | Anti-inflammation (block the action of inflammatory mediators) | [ |
| Methylprednisolone | Anti-inflammation (block the action of inflammatory mediators) | [ |
| Betamethasone | Anti-inflammation (block the action of inflammatory mediators) | [ |
| Hyaluronidase | Hydrolyze the hyaluronan | [ |
| Chymotrypsin | Hydrolyze the collagen | [ |
| Pentoxifylline | Anti-inflammation. | [ |
| Colchicine | Anti-inflammation, neutralized cytokines (TGF-β, IL4, IL6) | [ |
|
|
|
|
| Butylidenephthalide | Decrease α-SMA and fibronectin and type 1 collagen A1 expression | [ |
| Glabridin | Decrease α-SMA, type I collagen, and TGF-β | [ |
| Asiatic acid | Inhibit TGF-β1, collagen 1 type 2, and collagen 3 type 1 | [ |
| Tanshinone | reactivate p53 | [ |
| Salvianolic acid B with | Inhibit the transcription of procollagen gene COL1A1 and COL3A1 | [ |
| EGCG | Inhibit TGF-β1 to suppress early growth response-1 (Egr-1) | [ |
| Aloe Vera | Anti-inflammation | [ |
| Curcumin | Inhibit p53, TGF-β, and iNOS | [ |
| Lycopene | Antioxidants | [ |
| Honey | Anti-inflammation, anti-oxidation | [ |